Implantable cardioverter-defibrillator therapy in primary versus secondary prevention: Reliable prediction of appropriate therapies and mortality is still an unmet need.
作者信息
Tsuji Yukiomi, Dobrev Dobromir
机构信息
Department of Physiology of Visceral Function and Body Fluid, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Essen, Germany.
出版信息
Int J Cardiol Heart Vasc. 2021 Feb 23;32:100740. doi: 10.1016/j.ijcha.2021.100740. eCollection 2021 Feb.
Abstract
摘要
相似文献
1
Implantable cardioverter-defibrillator therapy in primary versus secondary prevention: Reliable prediction of appropriate therapies and mortality is still an unmet need.
Int J Cardiol Heart Vasc. 2021 Feb 23;32:100740. doi: 10.1016/j.ijcha.2021.100740. eCollection 2021 Feb.
2
Mortality Implications of Appropriate Implantable Cardioverter Defibrillator Therapy in Secondary Prevention Patients: Contrasting Mortality in Primary Prevention Patients From a Prospective Population-Based Registry.
J Am Heart Assoc. 2017 Aug 19;6(8):e006220. doi: 10.1161/JAHA.117.006220.
3
Primary prevention of sudden cardiac death by implantable cardioverter-defibrillator therapy in Chinese patients with heart failure: a single-center experience.
Chin Med J (Engl). 2010 Apr 5;123(7):848-51.
4
Clinical Impact of Implantable Cardioverter-Defibrillator Therapy and Mortality Prediction Model for Effective Primary Prevention in Korean Patients.
J Korean Med Sci. 2020 Mar 9;35(9):e49. doi: 10.3346/jkms.2020.35.e49.
5
Incidence of Implantable Cardioverter Defibrillator Therapy and Mortality in Primary and Secondary Prevention of Sudden Cardiac Death.
Isr Med Assoc J. 2015 Dec;17(12):760-3.
6
Usefulness of sleep-disordered breathing to predict occurrence of appropriate and inappropriate implantable-cardioverter defibrillator therapy in patients with implantable cardioverter-defibrillator for primary prevention of sudden cardiac death.
Am J Cardiol. 2013 May 1;111(9):1319-23. doi: 10.1016/j.amjcard.2013.01.277. Epub 2013 Feb 11.
7
Incidence of and predictors for appropriate implantable cardioverter-defibrillator therapy in patients with a secondary preventive implantable cardioverter-defibrillator indication.
Europace. 2016 Feb;18(2):227-31. doi: 10.1093/europace/euv188. Epub 2015 Jun 10.
8
Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.
Arch Intern Med. 2009 Sep 14;169(16):1500-6. doi: 10.1001/archinternmed.2009.255.
9
Update of implantable cardioverter/defibrillator and cardiac resynchronization therapy in heart failure.
Curr Opin Cardiol. 2004 May;19(3):264-9. doi: 10.1097/00001573-200405000-00012.
10
Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death.
Circ Arrhythm Electrophysiol. 2016 Mar;9(3):e003283. doi: 10.1161/CIRCEP.115.003283.
本文引用的文献
1
Comparison of second appropriate defibrillator therapy occurrence in patients implanted for primary prevention and secondary prevention - Sub-analysis of the Nippon Storm Study.
Int J Cardiol Heart Vasc. 2020 Dec 31;32:100704. doi: 10.1016/j.ijcha.2020.100704. eCollection 2021 Feb.
2
Is the clinical benefit of primary prevention implantable cardioverter-defibrillator overestimated? The role of sudden cardiac death to total mortality ratio.
Eur Heart J. 2020 Dec 14;41(47):4525-4526. doi: 10.1093/eurheartj/ehaa580.
3
Implantable Cardioverter-Defibrillators in Trials of Drug Therapy for Heart Failure: A Systematic Review and Meta-Analysis.
J Am Heart Assoc. 2020 Apr 21;9(8):e015177. doi: 10.1161/JAHA.119.015177. Epub 2020 Apr 15.
4
Antiarrhythmic Drugs or Catheter Ablation in the Management of Ventricular Tachyarrhythmias in Patients With Implantable Cardioverter-Defibrillators: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Circ Arrhythm Electrophysiol. 2019 Nov;12(11):e007600. doi: 10.1161/CIRCEP.119.007600. Epub 2019 Nov 8.
5
Electrical storm: mechanistic and therapeutic considerations to avoid death in the survivors.
J Thorac Dis. 2018 Nov;10(Suppl 33):S4053-S4056. doi: 10.21037/jtd.2018.09.111.
6
Mitochondrial ROS Drive Sudden Cardiac Death and Chronic Proteome Remodeling in Heart Failure.
Circ Res. 2018 Jul 20;123(3):356-371. doi: 10.1161/CIRCRESAHA.118.312708. Epub 2018 Jun 13.
7
Prognostic impact of electrical storm in patients with implantable cardioverter defibrillators: Mechanistic and therapeutic considerations to reduce the risk of death.
Int J Cardiol. 2018 Mar 15;255:101-102. doi: 10.1016/j.ijcard.2017.12.085.
8
Improvement of cardiomyocyte function by a novel pyrimidine-based CaMKII-inhibitor.
J Mol Cell Cardiol. 2018 Feb;115:73-81. doi: 10.1016/j.yjmcc.2017.12.015. Epub 2017 Dec 30.
9
Contemporary rates of appropriate shock therapy in patients who receive implantable device therapy in a real-world setting: From the Israeli ICD Registry.
Heart Rhythm. 2015 Dec;12(12):2426-33. doi: 10.1016/j.hrthm.2015.08.020. Epub 2015 Aug 13.
10
Role of RyR2 phosphorylation in heart failure and arrhythmias: Controversies around ryanodine receptor phosphorylation in cardiac disease.
Circ Res. 2014 Apr 11;114(8):1311-9; discussion 1319. doi: 10.1161/CIRCRESAHA.114.300568.
Zotero 插件